Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02229253

Enrollment

112

Registered

2014-09-01

Start date

2014-09-30

Completion date

2017-10-04

Last updated

2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Hormone Sensitive Prostate Cancer

Brief summary

Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.

Interventions

DRUGdegarelix

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Healthy volunteers

Inclusion criteria

* Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer

Exclusion criteria

* Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded * Planned intermittent or short-term (\< 12 months) degarelix treatment * Planned addition of, or switch to another form of androgen deprivation therapy during the study

Design outcomes

Primary

Measure	Time frame
Cardiovascular event rate in hormone naïve prostate cancer patients with cardiovascular comorbidity at baseline, treated with degarelix in daily practice	Up to 1 year

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026